REG-4basebio Plc: Result of AGM

4BasebioAnnouncement

Yesterday 18:15

27 June 2025

   
     


4basebio PLC

("4basebio" or the "Company")

Result of AGM

Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform, announces the result of its Annual General Meeting
held earlier today.

The Company decided at the meeting to make certain amendments to Resolutions
14 to 16 which were therefore withdrawn and replacement resolutions will be
put forward in due course.  All other resolutions were duly passed.

For further enquiries, please contact:

 4basebio PLC Dr. Heikki Lanckriet, CEO                                                +44 (0)1223 967 943  
 Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson / Ed Downes  +44 (0)20 7213 0880  
 Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes                      +44 (0)20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks               +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved